Mercator Medical reports a 170 percent profit rise: what it means for Mercator Medical stock

Published on 10/13/2026 at 05:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached PLN 337.2 million in the first half of 2026, up 16 percent. For Mercator Medical stock this means a PLN 1.64 dividend per share.

Key points in brief

Mercator Medical reported PLN 57.7 million net profit for the first half of 2026, up 170 percent year over year.
First-half revenue reached PLN 337.2 million, an increase of 16 percent from the prior year.
Management expects higher production and purchasing costs to pressure margins in subsequent quarters.
The next scheduled report is the third-quarter 2026 report on November 30, 2026.

Mercator Medical, PLMRCTR00015, Illustration mit AI erstellt.

Mercator Medical (PLMRCTR00015) reported PLN 57.7 million in net profit for the first half of 2026, up 170 percent year over year. The company presented the result on October 1, 2026, while management also warned that higher production and purchasing costs may weigh on margins in subsequent quarters, according to Mercator Medical.

Three results milestones

On August 21, 2026, Mercator Medical estimated second-quarter sales of PLN 191.0 million and net profit of PLN 44.4 million. The figures were later confirmed in the half-year reporting cycle, according to PPCG.

On October 1, 2026, the company reported first-half revenue of PLN 337.2 million, up 16 percent year over year, while EBITDA reached PLN 61.4 million compared with negative PLN 0.7 million a year earlier. Net profit rose from PLN 21.4 million to PLN 57.7 million, creating the article's 170 percent comparison, according to Mercator Medical.

On October 6, 2026, management said higher nitrite costs could reduce production-segment results in subsequent quarters, although distribution and Thai manufacturing margins were expected to remain above 2025 levels. The report also cited a cogeneration project costing PLN 51 million and a potential reduction of external electricity purchases by 95 percent, according to Investing.com.

What does the profit rise mean?

The improvement came from higher selling prices for diagnostic gloves, increased volumes, better purchasing terms and a more favorable sales mix. United States sales reached PLN 136.8 million in the first half, representing 40.6 percent of group sales and growth of 29.3 percent year over year, according to PAP Biznes.

Next reporting date

Mercator Medical's next scheduled event is the consolidated third-quarter 2026 report on November 30, 2026. The company paid a PLN 1.64 gross dividend per share on August 5, 2026, following the June 30, 2026 annual meeting, according to Mercator Medical.

Business and listing details

Mercator Medical manufactures disposable medical gloves and distributes single-use medical materials through operations serving more than 70 countries. Its shares have traded on the Warsaw Stock Exchange since 2013 and are included in the sWIG80 index.

The further course of trading is shown by the continuously updated real-time quote of Mercator Medical stock.